Connection

WOLFGANG WINKELMAYER to Drug Costs

This is a "connection" page, showing publications WOLFGANG WINKELMAYER has written about Drug Costs.
Connection Strength

0.180
  1. Potential savings in prescription drug costs for hypertension, hyperlipidemia, and diabetes mellitus by equivalent drug substitution in Austria: a nationwide cohort study. Appl Health Econ Health Policy. 2015 Apr; 13(2):193-205.
    View in: PubMed
    Score: 0.120
  2. Prevalence and determinants of unintended double medication of antihypertensive, lipid-lowering, and hypoglycemic drugs in Austria: a nationwide cohort study. Pharmacoepidemiol Drug Saf. 2016 Jan; 25(1):90-9.
    View in: PubMed
    Score: 0.031
  3. Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure. Circulation. 2005 Dec 13; 112(24):3745-53.
    View in: PubMed
    Score: 0.016
  4. The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int. 2003 Jul; 64(1):295-304.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.